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Abstract Resistance to taxanes, related to limited efﬁ-
cacy of systemic therapy in cancer patients, is multifacto-
rial. Among mechanisms of resistance to taxanes, those
related to microtubule-associated proteins (MAP), includ-
ing protein Tau, are of great importance. Protein Tau
(50–64 kD) binds to beta-tubulin in the same place as
paclitaxel. In preclinical studies, low expression of Tau in
cancer cells was associated with increased sensitivity to
paclitaxel. High expression of Tau protein in ER-positive
breast cancers indicates resistance to taxane-containing
chemotherapy and sensitivity to hormonal treatment. This
article reviews current knowledge on predictive value of
protein Tau in response to taxanes. Better understanding
of its role may facilitate patients selection to this sort of
treatment and lead to treatment optimization.
Keywords Protein Tau  Microtubules  Taxanes 
Chemoresistance
Introduction
Taxanes, which are widely used in clinical practice in the
treatment of gynaecological cancers (ovarian cancer, cer-
vical cancer and endometrial cancer), as well as many
others (breast, gastric and non-small-cell lung cancer), are
known to improve the patients’ outcome and prognosis.
However, it is likely that some patients do not beneﬁt from
the treatment due to the chemoresistance mechanisms.
Intrinsic chemoresistance appears on the early stage of
carcinogenesis and involves the lack of response to the
ﬁrst-line systemic treatment. Acquired chemoresistance
results from mutations and epigenetic changes in the cells
previously sensitive to the treatment.
Taxanes, paclitaxel and docetaxel interfere with spindle
microtubule dynamics causing cell cycle arrest and apop-
tosis. Protein Tau, one of microtubule-associated proteins
(MAP), may interact with paclitaxel due to the binding to
beta-tubulin in the same point.
This paper approaches the mechanisms of taxanes
activity, mechanisms of resistance to these agents, with a
particular consideration of the role of protein Tau in the
process.
Mechanisms of paclitaxel action
Paclitaxel was derived from the bark of the Paciﬁc yew
tree, Taxus brevifolia in 1962. Currently, it is produced in
semisynthetic way from Taxus baccata, and since 1992, it
has been widely used in clinical oncology.
Paclitaxel activity is connected with the spindle, con-
sisted of microtubules. While paclitaxel binds to a pocket in
beta-tubulin, on microtubule’s inner surface, the microtu-
buledepolimerizationprocessisinhibited[1].Microtubules,
usually dynamically unstable, are changing into stable
structures. It disables spindle division and causes cell cycle
arrest in phase G1/G2 of mitosis.
Cytotoxic effect of paclitaxel results also from the
induction of apoptosis by regulation of tumour suppressor
gene p53, as well as genes bcl-2 and bax. Disruption of
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cyclin-dependent kinases p21WAF1/CIP1 (p21) and leads
to phosphorylation of Bcl-2, associated with protein
kinases [2]. Phosphorylation of Bcl-2 protein induces the
apoptosis. Ling et al. [3] noticed increased phosphorylation
of Bcl-2 in cervical cancer cells HeLa subjected to pac-
litaxel, which caused cell cycle arrest in phase M of
mitosis.
Furthermore, Ferlini et al. [4] showed that paclitaxel
binds directly to Bcl-2, which elicits the apoptosis. The
authors presented a unique similarity between the paclit-
axel binding sites in Bcl-2 and beta-tubulin. They also
conﬁrmed that paclitaxel mimics Nur77, an endogenous
peptic ligand, in its structure and activity.
Paclitaxel enhances apoptosis through p53-independent
way, which probably involves bax gene. Patients with
mutant p53 tumours beneﬁt from addition of paclitaxel to
platinum-based chemotherapy [5, 6]. The inverse resis-
tance to paclitaxel and platinum agents, seen on cell
models, explains the clinical use of such chemotherapy
combination [7].
Mechanisms of the resistance to paclitaxel
Mechanisms of the resistance to chemotherapy are com-
plex and still rather little studied processes. They include
cellular transport disorder, aggravation of detoxication,
enhancement of DNA repair and interference with apop-
tosis. Additionally, resistance to taxanes results also from
alterations in microtubule dynamics.
In preclinical studies, P-glycoprotein (P-gp) efﬂux
pomp, a product of the multidrug resistance gene MDR1,
was identiﬁed as membrane-associated ATP-binding cas-
sette transporter, which decreased intracellular drug levels.
In many tumour cell lines, where P-gp was overexpressed,
drug cytotoxicity was limited. High P-gp expression is
related to cross-resistance to the following chemothera-
peutics: anthracyclines, vinca alkaloids, epipodophyllo-
toxines and taxanes. However, the role of P-gp in clinical
practice has not been established.
Changes in genetic material, caused by chemotherapy,
lead to p53 gene activation and beginning of DNA repair.
When DNA damage is too large or repair mechanisms not
adequate, apoptosis starts.
Tumour cell lines researches revealed that p53 gene
mutations are involved with drug resistance, and reversal of
its functions sensitizes tumour cells to chemotherapy [8]. It
is likely that the resistance to chemotherapy in the cells
with mutant p53 gene might be broken by the use of drugs,
which omit p53-dependent track of apoptosis, such as
microtubule-targeting agents, for example–taxanes [9].
Additionally, ovarian cancer patients with mutated p53
gene treated with paclitaxel better respond to the therapy
(86% of them) than patients with natural p53 gene (47%)
[10].
It is possible that the resistance to paclitaxel might be
caused also by the mechanisms involved with microtubules
and MAPs as the main target of taxanes action. Microtu-
bules are components of the cytoskeleton and with the
variety of functions such as intracellular transport, main-
tenance of cell shape, polarity, cell signalling and mitosis
[11]. They form mitotic spindle that transports daughter
chromosomes to separate poles of the dividing cell. And
that is why the anti-microtubule agents inhibit cancer cells
multiplication. Microtubules are polymers of alpha- and
beta-tubulin heterodimers, building tube-shaped ﬁlaments,
with (-) and (?) endings [12]. Microtubules, with their
dynamic nature, constant growing and shortening, caused
by the GTP-dependent association and dissociation of the
heterodimers at the both ends, are the crucial organelle
during cell division. Microtubule-associated proteins
(MAP) are attached to the microtubule-organizing centre
(MTOC). Some of them stabilize microtubules structure
(MAP2, MAP4, Tau, STOP, Mip-90 and statmin), other
modulate microtubule space arrangement (MAP1, MAP2
and Tau) or unable the organelle migration among micro-
tubules (kinesin, dynein and dynamin) [13].
Resistance to paclitaxel might result from the changes in
microtubule structure. Some preclinical studies showed the
correlation between overexpression of beta-tubulin class III
or class IVa and resistance to paclitaxel [14, 15]. Poor
prognostic value of the overexpression of beta-tubulin class
III or its inﬂuence on paclitaxel resistance was also con-
ﬁrmed in some clinical studies [16–19]. On the other hand,
the role of Tau and delta2-alpha-tubulin [17] nor statmin or
MAP4 [20] was not conﬁrmed in the process. Studies
assessing the prognostic value of beta-tubulin class III and
the correlation between its expression and beneﬁt from
paclitaxel are listed in the Table 1.
Structure of Tau protein and its role
in the resistance to paclitaxel
Tau protein (50–64 kD), a product of gene located in
chromosome 17 (17q21), was described for the ﬁrst time in
1975 [21]. Six isoforms are found, which are assigned to
one of two groups, depending on the number of domains
combined to tubulin (3R group includes Tau-3L, Tau-3S
and Tau 3, while 4R group includes Tau-4L, Tau-4S and
Tau-4). Tau activity is regulated in the phosphorylation
processes by serine threonine kinases [22].
As one of the MAPs, Tau shows the ability of combining
to tubulin. It may bind to the exterior as well as interior
microtubules surface, in the same binding site as paclitaxel,
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bined with Tau stabilizes microtubules in the same way as
paclitaxel, but with greater reversibility [23]. Tau overex-
pression enhances the polymerization and diminishes cells
ﬂexibility [24].
The role of Tau in the regulation of processes in the
nervous system is quite well known. Overphosphorylation
of this protein, occurring mainly in the axons, leads to
neuroﬁbrillary degeneration and is probably involved with
cells dysfunction and death. They are signiﬁcant in path-
ogenesis of Alzheimer’s disease as well as the other
‘‘taupathies’’ (Pick’s disease, Parkinson disease and fron-
totemporal dementia), which demonstrate clinically with
the limitation of cognitive functions [22].
Signiﬁcance of Tau in cancer diseases
The attempt to deﬁne the prognostic and predictive value of
Tau expression concerning mainly breast cancer patients
treated with taxanes has already been undertaken by some
researchers.
Several studies indicated that patients with low Tau
expression beneﬁt from paclitaxel therapy [25–29]. Among
82 breast cancer patients who were applied with paclitaxel-
based neoadjuvant chemotherapy, those with low Tau
mRNA expression achieved complete pathologic response
more frequently, with the statistical signiﬁcance
(P\0.001). At the same time, high Tau mRNA expression
was signiﬁcantly associated with no recurrence (at 5 and
10 years; P = 0.005 and P = 0.05, respectively) in
patients treated with tamoxifen, indicating a predictive
value for endocrine therapy. Additionally, high Tau mRNA
expression showed borderline non-signiﬁcant association
with better prognosis in the patients not receiving systemic
adjuvant therapy [25].
Tumours with pathologic complete response (pCR) to
preoperative paclitaxel-containing chemotherapy had sig-
niﬁcantly lower Tau mRNA expression. Therefore, Tau
expression was assessed immunohistochemically (IHC) in
122 independent patients applied neoadjuvant paclitaxel-
based treatment [26]. Among 31% of the patients who
achieved pCR, 74% of them had low Tau protein expression
(0, 1?). The odds ratio for pCR in Tau-negative tumours
was 3.7 (95% CI; 1.6–8.6; P = 0.0013). Furthermore,
suppression of Tau expression in breast cancer cell lines
(in vitro) with small interfering RNA (siRNA) increases
their sensitivity to paclitaxel, but not epirubicin [26].
Low expression of Tau protein (IHC) was correlatedwith
better time to disease progression in advanced breast cancer
patients (n = 35) treated with paclitaxel; 60% of Tau-
negative patients responded to chemotherapy, while 85% of
Tau-positive presented progressive or stable disease [27].
Other study, including 54 advanced breast cancer
patients receiving paclitaxel and cisplatin, showed that
high Tau protein expression (IHC) is an independent good
prognostic factor, while low Tau protein expression pre-
dicts response to chemotherapy [28].
Signiﬁcance of Tau expression was also evaluated in
one study concerning different than breast cancer site. The
analysis revealed that low Tau protein expression (0; 1?)
in advanced gastric cancer patients may predict beneﬁt
from paclitaxel-containing treatment. All the patients with
low Tau expression had clinical response conﬁrmed in
computed tomography (CT) examination, and 86% of the
patients with high Tau expression (2?;3 ?) did not take
any advantage from this therapy. Even though the study
group was not numerous (n = 20), the results are sug-
gesting that Tau expression may predict the response to
paclitaxel [29].
Conversely, in the retrospective analysis of 274 high-
risk early breast cancer patients treated with paclitaxel, the
predictive role of Tau was not conﬁrmed [30]. The authors
studied the prognostic and predictive role of oestrogen
receptor (ER) mRNA, progesterone receptor (PgR) mRNA
and Tau mRNA. Higher sensitivity to paclitaxel in low Tau
RNA tumours was observed only in ER-negative patients,
but not in ER-positive. It is possible that paclitaxel treat-
ment effects in low Tau RNA patients receiving also hor-
monal therapy (ER-positive) were interfered by resistance
to hormonal therapy. Tau mRNA expression is induced by
oestrogen and correlates with ER expression.
Table 1 Studies on the
correlation between expression
of beta-tubulin class III and
resistance to paclitaxel
NSCLC non-small-cell lung
cancer
Author Cancer site Expression of
beta-tubulin class III
Beneﬁt from
paclitaxel
Prognostic value of
beta-tubulin class III
Burkhart et al. [14] Breast, lung : No Not assessed
Kavallaris et al. [15] Ovary : No Not assessed
Seve et al. [16] Unknown : No Poor
Seve et al. [17] Unknown : No Poor
Seve et al. [18] NSCLC : No Poor
Ferrandina et al. [19] Ovary : Not assessed Poor
Aoki et al. [20] Ovary : Yes Not assessed
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expression was signiﬁcantly associated with reduced risk of
relapse (HR = 0.50; 95% CI; 0.32–0.78; P = 0.002) and
death (HR = 0.49; 95% CI; 0.29–0.83; P = 0.008) in
high-risk early breast cancer patients. Consequently, high
Tau mRNA was related to good prognosis in these patients.
Nevertheless, its signiﬁcance in predicting the response to
taxanes or hormones remains unclear. Considering rela-
tionship between Tau and oestrogen, further studies with
the separate analysis of ER-positive and ER-negative
patients are warranted.
In the presence of contradictory results of the studies,
the retrospective analysis of 1942 breast cancer patients
enrolled to NSABP-B28 study was of the great interest
[31]. The predictive and prognostic role of Tau expression
in breast cancer patients was assessed. The ER-positive and
ER-negative patients were analysed separately.
The correlation between Tau and ER was conﬁrmed.
High Tau expression was more frequent among ER-posi-
tive patients (57%) than ER-negative (15%). It was likely
that these disproportion resulted from the oestrogen regu-
lation of Tau gene. Tau expression is induced ‘‘in vitro’’ by
oestrogen as well as tamoxifen. In case, when ER-positive
patients were receiving tamoxifen for 5 years, Tau
expression could increase progressively during the therapy,
compared with the initial record.
Co-expression of Tau and ER was considered as a good
prognostic factor, involved with better overall survival
(OS) as well as disease-free survival (DFS). ER-positive
tumours with high Tau expression are sensitive to hor-
monal therapy and poorly respond to paclitaxel-containing
chemotherapy. In ER-negative tumours, prognostic value
of Tau was not conﬁrmed, but non-signiﬁcant trend of
better response to paclitaxel was noticed.
The authors of that study concluded that high Tau
expression in ER-positive patients is good prognostic fac-
tor, but, despite of ER status, predictive value of Tau for
paclitaxel treatment was not proved. The studies assessing
prognostic and predictive value of Tau are listed in the
Table 2.
Summary
Some studies revealed that low Tau expression is involved
with better response to paclitaxel [25–29]. Studies with
numerous groups of patients receiving paclitaxel did not
conﬁrm predictive value of Tau protein [30, 31]. Non-
signiﬁcant trend of higher sensitivity to paclitaxel in
ER-negative tumours suggests that Tau interactions with
oestrogen and tamoxifen may inﬂuence the results. Fur-
thermore, mechanisms of resistance are complex and hard
to explain on the basis of one marker. It is possible that
predictive value of low Tau expression does not exist or the
other molecular mechanisms, such as tubulin mutations,
expression of multidrug resistance proteins or Bcl-2, pre-
vail its signiﬁcance.
Modulation of response to taxanes by reduction of Tau
expression with siRNA remains a very interesting phe-
nomenon even though it had good results only in preclin-
ical researches on cancer cell lines [26].
At the same time, high Tau expression was conﬁrmed as
a good prognostic factor; however, in one study, this cor-
relation was observed only in ER-positive breast cancer
tumours [28, 30, 31].
In conclusion, Tau expression might be an important
biomarker of resistance to paclitaxel in other cancers
treated with taxanes. Its predictive and prognostic signiﬁ-
cance should be evaluated in well-projected prospective
studies. There is no doubt that treatment individualization
with the determination of predictive factors enhances
beneﬁts from the treatment and reduces its toxicity.
Conﬂict of interest All authors disclose any ﬁnancial and personal
relationships with other people or organizations that could inappro-
priately inﬂuence their work.
Table 2 Predictive and prognostic value of Tau
Study n Method of
Tau evaluation
Prognostic value Predictive value for
paclitaxel treatment
Andre et al. [25] 82 mRNA Possible (borderline signiﬁcance) Yes
Rouzier et al. [26] 122 Tau protein (IHC) Not assessed Yes
Tanaka et al. [27] 35 Tau protein (IHC) Not assessed Yes
Shao et al. [28] 54 Tau protein (IHC) Yes Yes
Mimori et al. [29] 20 Tau protein (IHC) Not assessed Yes
Pentheroudakis et al. [30] 274 mRNA Yes No (non-signiﬁcant
trend for ER-)
Pusztai et al. [31] 1,942 Tau protein (IHC) Yes (for ER?)N o
IHC immunohistochemistry
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